The role of vitamin D in gastrointestinal inflammation

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 8, 2014, Pages 909-923

  Ghaly, Simon ^a   Lawrance, Ian ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Immunoregulation; Inflammation; Inflammatory bowel disease; Treatment; Vitamin D

Indexed keywords

25 HYDROXYERGOCALCIFEROL; ANGIOGENIN; AUTOPHAGY RELATED 16 LIKE 1 PROTEIN; CALCIFEDIOL; CALCITRIOL; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLECALCIFEROL; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; OCCLUDIN; PLACEBO; PROTEIN; PROTEIN ZO2; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; VITAMIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ATG16L1 GENE; BACTERIAL IMMUNITY; CARCINOGENESIS; COLITIS; COLORECTAL CANCER; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DRUG DOSE ESCALATION; EPIDEMIOLOGICAL DATA; FRACTURE; GENE; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE MUCOSA PERMEABILITY; MEDICAL RESEARCH; NOD2 GENE; NONHUMAN; OBSERVATIONAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PTPN2 GENE; RELAPSE; REMISSION; REVIEW; RISK REDUCTION; ULCERATIVE COLITIS; ULTRAVIOLET RADIATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; COMPLICATION; INFLAMMATORY BOWEL DISEASES; PATHOLOGY;

HUMANS; INFLAMMATORY BOWEL DISEASES; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84911400332     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.925796     Document Type: Review

References (152)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140(6):1785-94
2. Wallace KL, Zheng L-B, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014;20(1):6-21
3. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol 2012; 76(3):315-25
4. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2012;142(3):482-9
5. Jørgensen SP, Hvas CL, Agnholt J, et al. Active Crohn's disease is associated with low vitamin D levels. J Crohns Colitis 2013;7(10):e407-13
6. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. J Parenter Enteral Nutr 2011;35(3):308-16
7. Harries AD, Brown R, Heatley RV, et al. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut 1985;26(11):1197-203
8. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013;19(9):1921-7
9. Ananthakrishnan AN, Cheng S-C, Cai T, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12(5):821-7
10. Zator ZA, Cantu SM, Konijeti GG, et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr 2014;38(3):385-91
11. Yang L, Weaver V, Smith JP, et al. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn's patients. Clin Transl Gastroenterol 2013;4:e33
12. Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Alimentary Pharmacol Ther 2010;32(3):377-83
13. Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther 2013;39(2):125-36
14. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96(1):53-8
15. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-30
16. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22(2):142-6
17. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7(5):439-43
18. Fu Y-TN, Chatur N, Cheong-Lee C, Salh B. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci 2012;57(8):2144-8
19. Pappa HM, Langereis EJ, Grand RJ, Gordon CM. Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;53(4):361-4
20. Alkhouri RH, Hashmi H, Baker RD, et al. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013;56(1):89-92
21. Joseph AJ, George B, Pulimood AB, et al. 25 (OH) vitamin D level in Crohn's disease: association with sun exposure and disease activity. Indian J Med Res 2009;130(2):133-7
22. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2014;109(2):163-9
23. Attard NR, Karran P. UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochem. Photobiol. Sci 2011;11(1):62-8
24. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol 2004;39(6):527-33
25. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010;376(9736):180-8
26. Powe CE, Evans MK, Wenger J, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013;369(21):1991-2000
27. Suibhne TN, Cox G, Healy M, et al. Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis 2012;6(2):182-8
28. Lawrance IC, Murray K, Batman B, et al. Crohn's disease and smoking: is it ever too late to quit? J Crohns Colitis 2013;7(12):e665-71
29. Liel Y, Ulmer E, Shary J, et al. Low circulating vitamin D in obesity. Calcif Tissue Int 1988;43(4):199-201
30. Zhou C, Assem M, Tay JC, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116(6):1703-12
31. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat Rev Immunol 2011;11(9):584-96
32. Holick MF, Tian XQ, Allen M. Evolutionary importance for the membrane enhancement of the production of vitamin D3 in the skin of poikilothermic animals. Proc Natl Acad Sci USA 1995;92(8)):3124-6
33. 3 and its photoisomers in human skin. Science 1982;216(4549):1001-3
34. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc 2011;86(1):50-60
35. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006;84(4):694-7
36. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008;93(3):677-81
37. Kawashima H, Torikai S, Kurokawa K. Localization of 25-hydroxyvitamin D3 1α-hydroxylase and 24-hydroxylase Along the Rat Nephron. Proc Natl Acad Sci USA 1981;78(2)):1199-203
38. Weisman Y, Harell A, Edelstein S, et al. 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature 1979;281(5729):317-19
39. Gray TK, Lester GE, Lorenc RS. Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. Science 1979;204(4399):1311-13
40. Adams JS, Gacad MA. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 1985;161(4):755-65
41. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86(2):888-94
42. Hewison M, Adams JS. Extrarenal 1α-Hydroxylase. In: David Feldman, J Wesley Pike and John S Adams, editors. Vitamin D. Elsevier; San Diego, CA, USA: 2011. p.777-804
43. Poon AH, Gong L, Brasch-Andersen C, et al. Very important pharmacogene summary for VDR. Pharmacogenet Genomics 2012;22(10):758-63
44. Zhang Y-G, Wu S, Sun J. Vitamin D, Vitamin D Receptor, and Tissue Barriers. Tissue Barriers 2013;1(1):pii: e23118
45. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008;294(1):G208-16
46. Christakos S, Dhawan P, Ajibade D, et al. Mechanisms involved in vitamin D mediated intestinal calcium absorption and in non-classical actions of vitamin D. J Steroid Biochem Mol Biol 2010;121(1-2):183-7
47. Rook GA, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986;57(1):159-63
48. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311(5768):1770-3
49. Lagishetty V, Chun RF, Liu NQ, et al. 1α-Hydroxylase and innate immune response to 25-hydroxyvitamin D in colonic cell lines. J Steroid Biochem Mol Biol 2010;121:228-33
50. Zaiou M, Gallo RL. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med (Berl) 2002;80(9):549-61
51. Wang T-T, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 2010;285(4):2227-31
52. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491(7422):119-24
53. Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology 2010;151(6):2423-32
54. Brennan A, Katz DR, Nunn JD, et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite. dihydroxycholecalciferol. Immunology 1987;61(4):457-61
55. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164(5):2405-11
56. Hewison M, Freeman L, Hughes SV, et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 2003;170(11):5382-90
57. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol 2010;321(2):103-11
58. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101(1):252-62
59. van Halteren AGS, van Etten E, de Jong EC, et al. Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 2002;51(7):2119-25
60. Bhalla AK, Amento EP, Clemens TL, et al. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 1983;57(6):1308-10
61. Provvedini DM, Manolagas SC. 1 Alpha,25-dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab 1989;68(4):774-9
62. Boonstra A, Barrat FJ, Crain C, et al. 1alpha,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001;167(9):4974-80
63. O'Kelly J, Hisatake J, Hisatake Y, et al. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002;109(8):1091-9
64. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 2008;10(6):568-75
65. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52(1):65-70
66. Bruce D, Yu S, Ooi JH, Cantorna MT. Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling. Int Immunol 2011;23(8):519-28
67. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008;324(1):23-33
68. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010;30(1):80-9
69. Gorman S, Kuritzky LA, Judge MA, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 2007;179(9):6273-83
70. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001;167(4):1945-53
71. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009;183(9):5458-67
72. Funderburg NT, Stubblefield Park SR, Sung HC, et al. Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013;140(1):87-97
73. Chen J, Bruce D, Cantorna MT. Vitamin D receptor expression controls proliferation of naïve CD8+ T cells and development of CD8 mediated gastrointestinal inflammation. BMC Immunol 2014;15(1):6
74. Yu S, Bruce D, Froicu M, et al. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci USA 2008;105(52):20834-9
75. Nerich V, Monnet E, Etienne A, et al. Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis 2006;12(3):218-26
76. Gorman S, Scott NM, Tan DHW, et al. Acute erythemal ultraviolet radiation causes systemic immunosuppression in the absence of increased 25-hydroxyvitamin D3 levels in male mice. PLoS One 2012;7(9):e46006
77. Bernard JJ, Cowing-Zitron C, Nakatsuji T, et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med 2012;18(8):1286-90
78. Soontrapa K, Honda T, Sakata D, et al. Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci USA 2011;108(16):6668-73
79. Sheibanie AF, Yen J-H, Khayrullina T, et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23->IL-17 axis. J Immunol 2007;178(12):8138-47
80. Lawrance IC, Chew AC, Lloyd F. Prostaglandin E2 regulates intestinal inflammation and modifies in vivo and in vitro extracellular matrix regulation. J Gastroenterol Hepatol 2012;27(suppl.4):622-23
81. Noonan FP, De Fabo EC. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. Immunol Today 1992;13(7):250-4
82. Kammeyer A, Peters CP, Meijer SL, Te Velde AA. Anti-inflammatory effects of urocanic Acid derivatives in models ex vivo and in vivo of inflammatory bowel disease. ISRN Inflamm 2012;2012:898153
83. Albert E, Walker J, Thiesen A, et al. cis-Urocanic acid attenuates acute dextran sodium sulphate-induced intestinal inflammation. PLoS ONE 2010;5(10):e13676
84. Hart PH, Gorman S. Exposure to UV Wavelengths in Sunlight Suppresses Immunity. To What Extent is UV-induced Vitamin D3 the Mediator Responsible? Clin Biochem Rev 2013;34(1):3-13
85. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20(10):1352-60
86. Gardiner EM, Esteban LM, Fong C, et al. Vitamin D receptor B1 and exon 1d: functional and evolutionary analysis. J Steroid Biochem Mol Biol 2004;89-90(1-5):233-8
87. Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988;85(10):3294-8
88. Miyamoto K, Kesterson RA, Yamamoto H, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997;11(8):1165-79
89. Jurutka PW, Remus LS, Whitfield GK, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 2000;14(3):401-20
90. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000;47(2):211-14
91. Noble CL, McCullough J, Ho W, et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;27(7):588-96
92. Bentley RW, Keown D, Merriman TR, et al. Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males. Aliment Pharmacol Ther 2011;33(7):855-6
93. Xue L-N, Xu K-Q, Zhang W, et al. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Inflamm Bowel Dis 2013;19(1):54-60
94. Ogunkolade B-W, Boucher BJ, Prahl JM, et al. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002;51(7):2294-300
95. Verbeek W, Gombart AF, Shiohara M, et al. Vitamin D receptor: no evidence for allele-specific mRNA stability in cells which are heterozygous for the Taq I restriction enzyme polymorphism. Biochem Biophys Res Commun 1997;238(1):77-80
96. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) 2010;88(5):441-50
97. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411(6837):599-603
98. Hedl M, Abraham C. Secretory mediators regulate Nod2-induced tolerance in human macrophages. Gastroenterology 2011;140(1):231-41
99. Verway M, Behr MA, White JH. Vitamin D, NOD2, autophagy and Crohn's disease. Expert Rev Clin Immunol 2010;6(4):505-8
100. Travassos LH, Carneiro LAM, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11(1):55-62
101. Scharl M, Paul G, Weber A, et al. Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2. Gastroenterology 2009;137(6):2030-40.e2035
102. Scharl M, McCole DF, Weber A, et al. Protein tyrosine phosphatase N2 regulates TNFα-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut 2011;60(2):189-97
103. Zhang J-X, He J-H, Wang J, et al. Associations between PTPN2 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Inflamm Res 2014;63(1):71-9
104. Garg M, Lubel JS, Sparrow MP, et al. Review article: vitamin D and inflammatory bowel disease - established concepts and future directions. Aliment Pharmacol Ther 2012;36(4):324-44
105. Eloranta JJ, Wenger C, Mwinyi J, et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011;21(9):559-64
106. Safadi FF, Thornton P, Magiera H, et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999;103(2):239-51
107. Speeckaert M, Huang G, Delanghe JR, Taes YEC. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372(1-2):33-42
108. Lauridsen AL, Vestergaard P, Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem 2001;47(4):753-6
109. Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (Vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005;77(1):15-22
110. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993;92(2):183-8
111. Gazouli M, Anagnostopoulos AK, Papadopoulou A, et al. Serum protein profile of Crohn's disease treated with infliximab. J Crohns Colitis 2013;7(10):e461-70
112. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39(5):690-7
113. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France. 1988Gut 1994;35(10):1433-8
114. Sonnenberg A. Demographic characteristics of hospitalized IBD patients. Dig Dis Sci 2009;54(11):2449-55
115. Jantchou P, Clavel-Chapelon F, Racine A, et al. High residential sun exposure is associated with a low risk of incident Crohn's disease in the prospective E3N cohort. Inflamm Bowel Dis 2014;20(1):75-81
116. Nerich V, Jantchou P, Boutron-Ruault M-C, et al. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther 2011;33(8):940-5
117. Garg M, Rosella O, Lubel JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2013;19(12):2634-43
118. Levin AD, Wadhera V, Leach ST, et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci 2011;56(3):830-6
119. Blanck S, Aberra F. Vitamin d deficiency is associated with ulcerative colitis disease activity. Dig Dis Sci 2013;58(6):1698-702
120. Ooi JH, Li Y, Rogers CJ, Cantorna MT. Vitamin d regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr 2013;143(10):1679-86
121. Liu N, Nguyen L, Chun RF, et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 2008;149(10):4799-808
122. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000;130(11):2648-52
123. Daniel C, Radeke HH, Sartory NA, et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther 2006;319(2):622-31
124. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxy vitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009;15(11):1656-62
125. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005;35(1):217-24
126. Bernstein CN, Leslie WD. Osteoporosis and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2004;19(9):941-52
127. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002;156(1):1-10
128. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133(10):795-9
129. Tang BMP, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370(9588):657-66
130. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337(10):670-6
131. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367(1):40-9
132. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293(18):2257-64
133. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326(7387):469
134. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005(3):CD000227
135. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014;383(9912):146-55
136. Dawson-Hughes B. Serum 25-hydroxyvitamin D and muscle atrophy in the elderly. Proc Nutr Soc 2012;71(1):46-9
137. van Langenberg DR, Gatta PD, Hill B, et al. Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. J Crohns Colitis 2014;8(7):626-34
138. Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis 2010;13(3):259-65
139. Souza HN, Lora FL, Kulak CA, et al. [Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density]. Arq Bras Endocrinol Metabol 2008;52(4):684-91
140. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37(2):192-9
141. Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003;98(11):2468-73
142. Tan B, Li P, Lv H, et al. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease. J Dig Dis 2014;15(3):116-23
143. Pereira F, Larriba MJ, Muñoz A. Vitamin D and colon cancer. Endocr Relat Cancer 2012;19(3):R51-71
144. Wada K, Tanaka H, Maeda K, et al. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 2009;22(5):1021-5
145. Lu R, Wu S, Xia Y, Sun J. The Vitamin D Receptor, Inflammatory Bowel Diseases, and Colon Cancer. Curr Colorectal Cancer Rep 2012;8(1):57-65
146. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9(3):227-31
147. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011;128(6):1414-24
148. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011;29(28):3775-82
149. Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(12):827-38
150. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85(6):1586-91
151. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013;11(12):1601-8.e1601-1604
152. Hassan V, Hassan S, Seyed-Javad P, et al. Association between Serum 25(OH)D Vitamin D concentrations and inflammatory bowel diseases (IBDs) activity. Med J Malaysia 2013;68:34-8